chr8:31496738:> Detail (hg19) (NRG1)

Information

Genome

Assembly Position
hg19 chr8:31,496,738-32,631,564
hg38 chr8:31,639,222-32,774,046 

HGVS

Type Transcript Protein
Summary

MGeND

Clinical significance
Variant entry
GWAS entry
Disease area statistics Show details

Frequency

[No Data.]

Prediction

[No Data.]

ClinVar

Clinical Significance
Review star [No Data.]
Show details
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease Drug EL ET ED CS VO TR Pubmed Links
pancreatic adenocarcinoma Afatinib C Predictive Supports Sensitivity/Response Somatic 4 29802158 Detail
DisGeNET
[No Data.]
Annotation

Annotations

DescrptionSourceLinks
In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These a... CIViC Evidence Detail

Overlapped Transcript Coordinates

Gene Transcript ID Exon Number Chromosome Start Stop Type Amino Mutation Transcript Position Links

Overlapped Transcript

Gene Transcript ID Chromosome Start Stop Links
Gene
-
Genome
hg19
Position
chr8:31,496,738-32,631,564
Variant Type
snv
Variant (CIViC) (CIViC Variant)
NRG1 FUSIONS
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/2286
Summary (CIViC Variant)
NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.
Variant (CIViC) (CIViC Variant)
FUSION
Variant URL (CIViC Variant)
https://civic.genome.wustl.edu/links/variants/2762
Genome browser